Checkpoint Therapeutics Q3 2021 Earnings Report
Key Takeaways
Checkpoint Therapeutics reported its Q3 2021 financial results, highlighting increased preparation activities for a potential Biologics License Application submission for cosibelimab next year. Substantial progress was made towards the near-term initiation of a Phase 3 registration-enabling trial for cosibelimab in first-line metastatic non-small cell lung cancer.
Preparation activities increased for a potential Biologics License Application submission for cosibelimab next year.
Awaited top-line results from registration-enabling study in metastatic cutaneous squamous cell carcinoma.
Made substantial progress towards the near-term initiation of Phase 3 registration-enabling trial for cosibelimab in first-line metastatic non-small cell lung cancer.
Continued to hire key personnel to position the company for the transition into a fully-integrated biopharmaceutical company.
Checkpoint Therapeutics
Checkpoint Therapeutics
Forward Guidance
The coming months could be transformational for Checkpoint Therapeutics, as the company continues to hire key personnel to position it favorably for the transition into a fully-integrated biopharmaceutical company focused on the goal of offering cancer therapies that provide better patient outcomes while delivering significant value to the future of healthcare.